<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01944800</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE 00113</org_study_id>
    <secondary_id>2013-002272-40</secondary_id>
    <nct_id>NCT01944800</nct_id>
  </id_info>
  <brief_title>Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome</brief_title>
  <acronym>ISAR-REACT 5</acronym>
  <official_title>Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the randomized, open-label, multicenter ISAR-REACT 5 trial is to assess whether
      ticagrelor is superior to prasugrel in patients with acute coronary syndrome and planned
      invasive strategy in terms of clinical outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 15, 2013</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of death, myocardial infarction or stroke</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Bleeding according to BARC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>12 months</time_frame>
    <description>Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Stent thrombosis according to ARC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Acute Coronary Syndrome (ACS)</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Loading dose of 180 mg, followed by maintenance dose of 180 mg per day</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/&gt; 75 years or &lt; 60 kg</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Efient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

        Hospitalization for an acute coronary syndrome (ST-segment elevation myocardial infarction,
        non-ST-segment elevation myocardial infarction or unstable angina pectoris) with planned
        invasive strategy

        Major Exclusion Criteria:

          1. intolerance of or allergy to ticagrelor or prasugrel

          2. history of any stroke, transient ischemic attack or intracranial bleeding

          3. known intracranial neoplasm, intracranial arteriovenous malformation or intracranial
             aneurysm

          4. active bleeding, clinical findings, that in the judgement of the investigator are
             associated with an increased risk of bleeding

          5. fibrin-specific fibrinolytic therapy less than 24 h before randomization,
             non-fibrin-specific fibrinolytic therapy less than 48 h before randomization

          6. known platelet count &lt; 100.000/μL at the time of screening

          7. known anemia (hemoglobin &lt;10 g/dL) at the time of screening

          8. oral anticoagulation that cannot be safely discontinued for the duration of the study

          9. INR known to be greater than 1.5 at the time of screening

         10. chronic renal insufficiency requiring dialysis

         11. moderate or severe hepatic dysfunction (Child Pugh B or C)

         12. increased risk of bradycardia events (Sick Sinus, AV block grade II or III,
             bradycardia-induced syncope)

         13. index event is an acute complication (&lt; 30 days) of PCI

         14. concomitant medical illness that in the opinion of the investigator is associated with
             a life expectancy &lt; 1 year

         15. concomitant oral or i.v. therapy with strong CYP3A Inhibitors (e.g. ketoconazole,
             itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir,
             saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice &gt; 1 L/d), CYP3A
             substrates with narrow therapeutic indices (e.g. cyclosporine, quinidine), or strong
             CYP3A inducers (e.g. rifampin/rifampicin, phenytoin, carbamazepine, dexamethason,
             phenobarbital ) that cannot be safely discontinued

         16. ≥1 doses of ticagrelor or prasugrel within 5 days before randomisation

         17. no written informed consent

         18. participation in another investigational drug study

         19. previous enrolment in this study

         20. for women of childbearing potential no negative pregnancy test and no agree to use
             reliable method of birth control during the study

         21. Pregnancy, giving birth within the last 90 days, or lactation

         22. inability to cooperate with protocol requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefanie Schuepke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg/ Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <state>Baden-Württemberg</state>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Klinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Landkreis Erding</name>
      <address>
        <city>Erding</city>
        <state>Bavaria</state>
        <zip>85435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Munich</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, 1. Medizinische Klinik und Poliklinik</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Neuperlach</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Traunstein</name>
      <address>
        <city>Traunstein</city>
        <state>Bavaria</state>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik GmbH, Abteilung für Kardiologie</name>
      <address>
        <city>Bad Nauheim</city>
        <state>Hessen</state>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen, Herzzentrum</name>
      <address>
        <city>Göttingen</city>
        <state>Niedersachsen</state>
        <zip>37099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken GmbH</name>
      <address>
        <city>Bad Segeberg</city>
        <state>Schleswig-Holstein</state>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Klinik für Innere Medizin III, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, Campus Virchow-Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Careggi University Hospital, Invasive Cardiology Division</name>
      <address>
        <city>Firenze</city>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaziani Hospital Frosinone</name>
      <address>
        <city>Frosinone</city>
        <zip>03100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 13, 2013</study_first_submitted>
  <study_first_submitted_qc>September 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2013</study_first_posted>
  <last_update_submitted>July 13, 2019</last_update_submitted>
  <last_update_submitted_qc>July 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ticagrelor</keyword>
  <keyword>Prasugrel</keyword>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

